Trial Profile
AST 915 in patients with essential tremor.
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 24 Dec 2010
Price :
$35
*
At a glance
- Drugs AST 915 (Primary)
- Indications Essential tremor
- Focus Adverse reactions
- 16 Dec 2010 Results are expected to be presented at the 15th International Congress of Parkinson's Disease and Movement Disorders, according to a Manhattan Pharmaceuticals media release.
- 16 Dec 2010 Primary endpoint 'Clinical-response' has not been met, according to a Manhattan Pharmaceuticals media release.
- 16 Dec 2010 Interim results reported in a Manhattan Pharmaceuticals media release.